Abstract 22P
Background
In the phase 1 GARNET study, Dostarlimab (Dmab) a PD-1 inhibitor, demonstrated clinically meaningful and durable antitumor activity in patients (pts) with advanced/ metastatic mismatch repair deficient endometrial cancer (Adv MMRd EC) after chemotherapy (chemo). Recently, the RUBY trial showed a significant improvement in progression-free survival (PFS) with Dmab plus chemo vs chemo alone, changing the standard of care in the first-line setting of Adv MMRd EC. To date, there are no validated predictive biomarkers of response to Dmab. There is growing evidence that tertiary lymphoid structure (TLS) could be predictive of response and prognostic in early EC. In our pilot study, we aim to determine the predictive value of TLS in Adv MMRd EC.
Methods
Pts with Adv MMRd EC treated with Dmab as a second-line after chemo in GARNET and the French early access program at Institut Paoli-Calmettes were included. Tissue samples from hysterectomy, endometrial or metastasis biopsies were collected. Microscopic examination was performed using paraffin-embedded tissue blocks on HES-stained sections. The presence of TLS was defined by histomorphological and phenotypic (immunohistochemistry) criterias: a dense nodule of more than 200 closely grouped lymphoid cells, with an occasional germinal center; a mixture of CD20+ B cells forming a follicle and surrounded by CD3+ T cells. Mature TLS were defined by the presence of follicular dendritic cells CD23+, CD21+, L1CAM+.
Results
14 pts were included from 12/2017-10/2021. One patient was excluded (tissue sample not evaluable). 11/13 (84%) pts had endometrioid EC. TLS were identified in 6/13 (46%) pts (TLS+) on HES sections. Immunohistochemistry staining confirmed the diagnosis of TLS, but did not detect further TLS. Median PFS : 9 months in pts with TLS vs 3.5 months in pts with no TLS.
Conclusions
Presence of TLS on HES sections seemed associated with better PFS in Adv MMRd EC pts treated with second-line Dmab. HES seemed sufficient to identify TLS, and could in routine practice, help better select MMRd pts that could benefit from Dmab alone. Larger cohorts are required to confirm our observations and explore predictive factors of reponse to Dmab in first-line.
Legal entity responsible for the study
Institut Paoli-Calmettes.
Funding
Has not received any funding.
Disclosure
M. Kfoury: Financial Interests, Personal, Invited Speaker: AZ, GSK. F. Rousseau: Financial Interests, Personal, Financially compensated role: Eisai; Financial Interests, Personal, Other: Viatris. R. Sabatier: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Invited Speaker: Eisai, Clovis Oncology; Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Personal, Other, Travel fees: MSD, Novartis; Non-Financial Interests, Personal, Other, Congress fees: GSK. All other authors have declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display
100P - Phase II trial of tislelizumab plus bevacizumab and chemotherapy as the first-line therapy for persistent, recurrent, or metastatic cervical cancer: updated efficacy and safety results
Presenter: Jianqing Zhu
Session: Poster Display